| Oct-19-17 12:45PM | Editas Medicine Demonstrates Dose-Dependent, In Vivo Editing with EDIT-101 in CEP290 Transgenic Mice GlobeNewswire |
| Oct-03-17 08:00AM | Editas Medicine to Participate in Investor Conferences in October GlobeNewswire |
| Oct-02-17 04:10PM | Why Bluebird's Downgrade Sent These Two Rivals Skyrocketing Investor's Business Daily |
| Sep-27-17 09:46AM | Axovant Rises After Tuesday's Plunge - Biotech Movers TheStreet.com |
| Sep-26-17 04:01PM | Editas Medicine Receives EMAs Orphan Medicinal Product Designation for EDIT-101 for the Treatment of LCA10 GlobeNewswire |
| Sep-12-17 08:00AM | Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type 10 (LCA10) GlobeNewswire |
| Sep-07-17 09:30PM | Why Gene-Editing Pioneer Editas Skyrocketed 28.8% in August Motley Fool |
| Sep-05-17 08:00AM | Editas Medicine to Participate in Morgan Stanley 15th Annual Global Healthcare Conference GlobeNewswire |
| Aug-31-17 11:29AM | How a CRISPR, gene-editing technology, patent ruling could move stocks Harvest Exchange |
| Aug-20-17 02:02PM | This Stock Could Be the Tesla of Healthcare Motley Fool |
| Aug-14-17 08:16PM | Edited Transcript of EDIT earnings conference call or presentation 9-Aug-17 9:00pm GMT Thomson Reuters StreetEvents +5.51% |
| 08:15AM | Editas Medicine (EDIT) Looks Good: Stock Moves Up 11.3% Zacks |
| 07:30AM | [$$] Gormley's Take: Biotech Companies Are Steering Clear of Gene Editing's Ethical Concerns The Wall Street Journal |
| Aug-13-17 07:06AM | Edited Transcript of EDIT earnings conference call or presentation 15-May-17 9:00pm GMT Thomson Reuters StreetEvents |
| Aug-09-17 10:02PM | Editas reports 2Q loss Associated Press |
| 04:03PM | Editas Medicine Announces Second Quarter 2017 Results and Update GlobeNewswire |
| 04:01PM | Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment GlobeNewswire |
| Aug-08-17 09:56AM | Here's Why Editas Medicine Rose as Much as 15.9% Monday Motley Fool |
| Aug-07-17 08:00AM | Editas Medicine to Host Conference Call Discussing Second Quarter 2017 Corporate Update and Results GlobeNewswire +9.09% |
| Jul-31-17 08:36AM | Editas Medicine, Inc. breached its 50 day moving average in a Bullish Manner : EDIT-US : July 31, 2017 Capital Cube |
| Jul-24-17 03:34PM | ETFs with exposure to Editas Medicine, Inc. : July 24, 2017 Capital Cube |
| Jul-18-17 09:31AM | Should You Buy Into the Hype Surrounding These Stocks? Motley Fool -5.10% |
| 08:10AM | Today's Research Reports on Stocks to Watch: Editas Medicine and Cymabay Therapeutics Accesswire |
| Jul-15-17 03:40PM | Never Will I Ever Buy Preclinical Biotech Stocks. No Way! Motley Fool |
| Jul-14-17 02:06PM | ETFs with exposure to Editas Medicine, Inc. : July 14, 2017 Capital Cube |
| Jul-11-17 05:08PM | Here's Why Editas Medicine Inc. Bounced Up 20% in June Motley Fool |
| 09:16AM | Editas Medicine, Inc. breached its 50 day moving average in a Bearish Manner : EDIT-US : July 11, 2017 Capital Cube |
| Jul-03-17 04:23PM | Editas Medicine, Inc. Value Analysis (NASDAQ:EDIT) : July 3, 2017 Capital Cube |
| Jun-30-17 09:27AM | Editas Medicine, Inc. breached its 50 day moving average in a Bearish Manner : EDIT-US : June 30, 2017 Capital Cube |
| Jun-13-17 08:00AM | Editas Medicine to Participate in Investor Conferences in June GlobeNewswire |
| May-31-17 04:01PM | Editas Medicine Names Andrew Hirsch to Board of Directors GlobeNewswire |
| 08:00AM | Today's Research Reports on Stocks to Watch: Valeant Pharmaceuticals and Editas Medicine Accesswire |
| May-30-17 04:50PM | Study raises concerns over gene-editing, hitting Cambridge biotechs hard American City Business Journals -11.97% |
| 04:17PM | Here's Why Editas Medicine Fell as Much as 15.7% Today Motley Fool |
| May-16-17 01:40PM | Is Editas Facing a New Reality in CRISPR Land? 24/7 Wall St. -8.55% |
| 09:34AM | Biotech Movers: Akebia, Editas, Novavax TheStreet.com |
| May-15-17 06:32PM | Editas reports 1Q loss Associated Press |
| 04:01PM | Editas Medicine Announces First Quarter 2017 Results and Update GlobeNewswire |
| 03:30PM | Investor Network: Editas Medicine, Inc. to Host Earnings Call Accesswire |
| May-13-17 11:05AM | Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas GlobeNewswire |
| May-12-17 08:45AM | Why Editas Medicine (EDIT) Might Surprise This Earnings Season Zacks |
| May-11-17 09:15AM | Editas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia GlobeNewswire |
| May-09-17 05:42PM | Allergan Says It Continues to Look at Stepping-Stone Deals TheStreet.com |
| 09:48AM | Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store? Zacks |
| May-08-17 04:01PM | Editas Medicine to Present at Investor Conferences in May GlobeNewswire |
| 04:01PM | Editas Medicine to Host Conference Call Discussing First Quarter 2017 Corporate Update and Results GlobeNewswire |
| 02:45PM | Cambridge gene editing firm CRISPR to use delivery tech honed at MIT American City Business Journals |
| Apr-27-17 11:35AM | CEOs of top gene-editing firms got huge compensation hikes last year American City Business Journals |
| Apr-25-17 09:29AM | Opening Bell, April 25, 2017 CNBC Videos |
| 09:15AM | Today's Bell Ringer, April 25, 2017 CNBC Videos |
| Apr-24-17 02:18PM | Editas Medicine to Present New Data Demonstrating Advancements for Translating CRISPR Technologies into Medicines at the American Society of Gene & Cell Therapy Annual Meeting GlobeNewswire |
| 10:00AM | Editas Medicine, Inc. (Nasdaq: EDIT) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire |
| Apr-13-17 02:05PM | Editas foes add legal firepower as gene-editing case goes to appeal American City Business Journals |
| Mar-31-17 04:09PM | EDITAS MEDICINE, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-Bal |
| Mar-30-17 07:20AM | New Cambridge biotech Tango aims to make cancer its own worst enemy at bizjournals.com |
| 07:20AM | New Cambridge biotech Tango aims to make cancer its own worst enemy American City Business Journals |
| Mar-29-17 08:11AM | Editas Medicine, Inc. breached its 50 day moving average in a Bullish Manner : EDIT-US : March 29, 2017 Capital Cube |
| 08:11AM | Editas Medicine, Inc. breached its 50 day moving average in a Bullish Manner : EDIT-US : March 29, 2017 |
| Mar-28-17 06:04AM | Coverage initiated on Editas Medicine by Chardan Capital Markets +5.75% |
| Mar-22-17 10:30AM | Latest Editas research pact could be worth up to $1 billion at bizjournals.com |
| 10:30AM | Latest Editas research pact could be worth up to $1 billion American City Business Journals |
| Mar-20-17 04:51PM | Editas Get A Vetr Upgrade To Strong Buy Benzinga |
| Mar-17-17 04:50PM | EDITAS MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stateme -10.48% |
| Mar-16-17 09:05PM | Editas Medicine, Inc. Announces Pricing of $90 Million Offering of Common Stock GlobeNewswire |
| 02:12PM | [$$] EGenesis Raises $38 Million Series A, Targets Organ Shortage The Wall Street Journal |
| 02:12PM | [$$] EGenesis Raises $38 Million Series A, Targets Organ Shortage at The Wall Street Journal |
| 12:50AM | Pig organs in humans? George Church-founded biotech banks $38M to try at bizjournals.com |
| 12:50AM | Pig organs in humans? George Church-founded biotech banks $38M to try American City Business Journals |
| Mar-15-17 05:46PM | Allergan (AGN) and Editas Tie Up to Treat Eye Diseases Zacks -5.38% |
| 04:14PM | Editas Medicine, Inc., Announces Proposed Offering of Common Stock GlobeNewswire |
| 08:46AM | EDITAS MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement |
| Mar-14-17 05:24PM | Here's Why Editas Medicine Gained as Much as 17.2% Today at Motley Fool |
| 04:30PM | Allergan plc and Editas Medicine Inc Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases Call scheduled for 4:30 pm ET today |
| 11:25AM | CRISPR Could Change The World, But Right Now $90 Million Is Enough at Forbes |
| 11:15AM | Allergan, Editas In Gene-Editing Eye Disease Pact at Investopedia |
| 09:59AM | Allergan, Editas Sign Gene-Editing Pact for Rare Eye Diseases |
| 09:26AM | Biotech Premarket Movers: Editas, Amphastar, Aratana, Pacira |
| 09:00AM | Editas bags $90M in gene editing R&D pact with Allergan at bizjournals.com |
| 08:35AM | Editas Medicine surges 8% on $90 million Allergan research and development deal at MarketWatch |
| 08:22AM | Allergan signs deal with Editas for gene-editing-based eye treatments |
| 08:00AM | Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases PR Newswire |
| Mar-09-17 01:04PM | EDITAS MEDICINE, INC. Financials +8.02% |
| 10:41AM | Editas Medicine, Inc. :EDIT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 9, 2017 |
| Mar-08-17 02:50PM | Intellia R&D head says new gene-editing data shows path to human trials at bizjournals.com |
| 12:53AM | Edited Transcript of EDIT earnings conference call or presentation 7-Mar-17 10:00pm GMT |
| Mar-07-17 07:46PM | Editas reports 4Q loss |
| 05:00PM | Editas Medicine Inc Earnings Call scheduled for 5:00 pm ET today |
| 04:10PM | EDITAS MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibi |
| 04:01PM | Editas Medicine Announces Fourth Quarter and Full Year 2016 Results and Update GlobeNewswire |
| 07:07AM | Q4 2016 Editas Medicine Inc Earnings Release - After Market Close |
| Mar-06-17 01:00PM | New Cambridge-based, Third Rock-backed biotech revealed in federal filing at bizjournals.com |
| 12:31PM | 3 Stocks I'd Never Touch at Motley Fool |
| Mar-03-17 09:10AM | Editas Medicine COO to Leave Company -6.81% |
| 09:07AM | EDITAS MEDICINE, INC. Files SEC form 8-K, Change in Directors or Principal Officers |
| 09:00AM | Editas Medicine Announces Departure of Chief Operating Officer GlobeNewswire |
| Feb-28-17 04:01PM | Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2016 Corporate Update and Results GlobeNewswire +8.39% |
| 08:00AM | Editas Medicine Joins Global Movement to Raise Awareness on Rare Disease Day 2017 GlobeNewswire |
| Feb-27-17 04:01PM | Editas Medicine to Present at Investor Conferences in March GlobeNewswire |
| Feb-21-17 05:00AM | How Much Is a CRISPR Patent License Worth? at Forbes |
| Feb-17-17 02:36PM | Court Rules Against Berkeley In CRISPR Patent Case at Investopedia +5.13% |
|
|
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Bosley Katrine | President and CEO | Oct 02 | Sale | 24.78 | 8,333 | 206,525 | 1,399,430 | Oct 04 04:30 PM | | Bosley Katrine | President and CEO | Sep 05 | Sale | 20.20 | 6,666 | 134,681 | 1,407,763 | Sep 06 05:05 PM | | Bosley Katrine | President and CEO | Sep 01 | Sale | 20.42 | 10,000 | 204,150 | 1,414,429 | Sep 06 05:05 PM | | Bosley Katrine | President and CEO | Aug 11 | Sale | 20.02 | 6,666 | 133,450 | 1,424,429 | Aug 14 04:35 PM | | Bosley Katrine | President and CEO | Aug 10 | Sale | 20.02 | 10,000 | 200,160 | 1,431,095 | Aug 14 04:35 PM | | Cox Gerald Frank | Chief Medical Officer | Jun 02 | Buy | 14.15 | 4,000 | 56,600 | 4,000 | Jun 06 04:12 PM | | Nikolic Boris | Director | Jun 02 | Buy | 14.07 | 35,000 | 492,527 | 35,000 | Jun 06 04:09 PM | | Bitterman Kevin | Director | May 22 | Sale | 17.00 | 1,000,000 | 17,000,000 | 2,797,144 | May 24 04:38 PM | | Glucksmann Alexandra | Chief Operating Officer | Mar 15 | Option Exercise | 0.65 | 1,000 | 650 | 118,788 | Mar 17 11:53 AM | | Glucksmann Alexandra | Chief Operating Officer | Mar 15 | Sale | 26.41 | 1,000 | 26,410 | 117,788 | Mar 17 11:53 AM | | Glucksmann Alexandra | Chief Operating Officer | Feb 15 | Option Exercise | 0.65 | 6,000 | 3,900 | 123,788 | Feb 16 06:39 PM | | Hack Andrew A. F. | Chief Financial Officer | Feb 15 | Option Exercise | 3.23 | 3,000 | 9,690 | 3,000 | Feb 16 06:41 PM | | Hack Andrew A. F. | Chief Financial Officer | Feb 15 | Sale | 19.20 | 3,000 | 57,600 | 0 | Feb 16 06:41 PM | | Glucksmann Alexandra | Chief Operating Officer | Feb 15 | Sale | 20.58 | 6,000 | 123,484 | 117,788 | Feb 16 06:39 PM | | Hack Andrew A. F. | Chief Financial Officer | Jan 11 | Option Exercise | 3.23 | 15,000 | 48,450 | 15,000 | Jan 13 04:41 PM | | Hack Andrew A. F. | Chief Financial Officer | Jan 11 | Sale | 19.20 | 15,000 | 288,000 | 0 | Jan 13 04:41 PM | | Polaris Venture Management Co. | 10% Owner | Dec 07 | Sale | 15.82 | 75,000 | 1,186,500 | 3,797,144 | Dec 08 05:07 PM | | Bitterman Kevin | Director | Dec 07 | Sale | 15.82 | 75,000 | 1,186,500 | 3,797,144 | Dec 08 05:07 PM | | Bitterman Kevin | Director | Dec 06 | Sale | 15.87 | 50,000 | 793,500 | 3,872,144 | Dec 07 04:43 PM | | Polaris Venture Management Co. | 10% Owner | Dec 06 | Sale | 15.87 | 50,000 | 793,500 | 3,872,144 | Dec 07 04:44 PM | | Polaris Venture Management Co. | 10% Owner | Dec 05 | Sale | 15.74 | 80,000 | 1,259,200 | 3,922,144 | Dec 07 04:44 PM | | Bitterman Kevin | Director | Dec 05 | Sale | 15.74 | 80,000 | 1,259,200 | 3,922,144 | Dec 07 04:43 PM | | Polaris Venture Management Co. | 10% Owner | Nov 23 | Sale | 15.71 | 21,480 | 337,451 | 4,002,144 | Nov 28 04:37 PM | | Bitterman Kevin | Director | Nov 23 | Sale | 15.71 | 21,480 | 337,451 | 4,002,144 | Nov 28 04:35 PM | | Polaris Venture Management Co. | 10% Owner | Nov 22 | Sale | 15.77 | 12,819 | 202,156 | 4,023,624 | Nov 23 04:38 PM | | Bitterman Kevin | Director | Nov 22 | Sale | 15.77 | 12,819 | 202,156 | 4,023,624 | Nov 23 04:36 PM | | Polaris Venture Management Co. | 10% Owner | Nov 16 | Sale | 16.30 | 30,830 | 502,529 | 4,036,443 | Nov 18 05:46 PM | | Bitterman Kevin | Director | Nov 16 | Sale | 16.30 | 30,830 | 502,529 | 4,036,443 | Nov 18 05:44 PM | | Polaris Venture Management Co. | 10% Owner | Nov 15 | Sale | 16.57 | 30,865 | 511,428 | 4,067,273 | Nov 16 04:47 PM | | Bitterman Kevin | Director | Nov 15 | Sale | 16.57 | 30,865 | 511,428 | 4,067,273 | Nov 16 04:47 PM | | Bitterman Kevin | Director | Nov 14 | Sale | 17.16 | 58,035 | 995,881 | 4,098,138 | Nov 16 04:47 PM | | Polaris Venture Management Co. | 10% Owner | Nov 14 | Sale | 17.16 | 58,035 | 995,881 | 4,098,138 | Nov 16 04:47 PM |
|
